To further these observations, we tested the same treatment regimens in ovalbumin-expressing EG7 tumor cells and observed similar patterns of tumor regression and immune activity (Supplementary Fig. S3A–S3D) between TPST-1495 and combined single EP2/EP4 receptor antagonists. Here, PTGER2 is linked to neoplasm.